Related Experiment Video
Updated: Jun 7, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms
1Division of Oncology, Departments of Medicine and Pathology, Stanford University, Stanford, CA, USA.
Abstract:
Tumorigenesis is generally caused by genetic changes that activate oncogenes or inactivate tumor suppressor genes. The targeted inactivation of oncogenes can be associated with tumor regression through the phenomenon of oncogene addiction. One of the most common oncogenic events in human cancer is the activation of the MYC oncogene. The inactivation of MYC may be a general and effective therapy for human cancer. Indeed, it has been experimentally shown that the inactivation of MYC can result in dramatic and sustained tumor regression in lymphoma, leukemia, osteosarcoma, hepatocellular carcinoma, squamous carcinoma, and pancreatic carcinoma through a multitude of mechanisms, including proliferative arrest, terminal differentiation, cellular senescence, induction of apoptosis, and the shutdown of angiogenesis. Cell-autonomous and cell-dependent mechanisms have both been implicated, and recent results suggest a critical role for autocrine factors, including thrombospondin-1 and TGF-β. Hence, targeting the inactivation of MYC appears to elicit oncogene addiction and, thereby, tumor regression through both tumor cell-intrinsic and host-dependent mechanisms.
Insights
Inactivating the MYC oncogene shows promise as a cancer therapy. This approach leverages oncogene addiction to induce tumor regression across various cancer types.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Tumorigenesis often involves genetic alterations activating oncogenes or deactivating tumor suppressor genes.
- Oncogene addiction describes tumor regression following targeted inactivation of activated oncogenes.
- MYC oncogene activation is a frequent event in human cancers.
Purpose of the Study:
- To investigate the therapeutic potential of MYC oncogene inactivation in cancer treatment.
- To explore the mechanisms underlying tumor regression induced by MYC inactivation.
Main Methods:
- Experimental inactivation of the MYC oncogene in various cancer models.
- Analysis of tumor regression and associated cellular and molecular changes.
- Investigation of cell-autonomous and cell-dependent mechanisms, including autocrine factors.
Main Results:
- MYC inactivation led to significant and sustained tumor regression in multiple cancer types (lymphoma, leukemia, osteosarcoma, etc.).
- Mechanisms of regression include proliferative arrest, differentiation, senescence, apoptosis, and anti-angiogenesis.
- Both cell-intrinsic and host-dependent pathways, involving factors like thrombospondin-1 and TGF-β, contribute to tumor regression.
Conclusions:
- Targeting MYC inactivation represents a potential broad-spectrum cancer therapy.
- This strategy exploits oncogene addiction, leading to tumor regression via diverse mechanisms.
- Both tumor cell-autonomous and host-mediated responses are crucial for therapeutic efficacy.
Related Concept Videos
Induced Pluripotent Stem Cells
Somatic cells are...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation

